



Press Release

Pharmalucence Announces Divestiture of AeroTech® Products to Biodex Medical Systems

Bedford, MA, August 11, 2008 – Pharmalucence, Inc. announced today that it has completed divestiture of its AeroTech product line to Biodex Medical Systems of Shirley, NY. Biodex begins product support and distribution immediately. Terms of the transaction were not disclosed.

About Pharmalucence, Inc.

Pharmalucence, Inc. is a specialty pharmaceutical company headquartered in Bedford, MA with a focus in the manufacture and marketing of molecular imaging agents and in providing contract manufacturing and development services for human parenteral compounds.

About Biodex Medical Systems, Inc.

Biodex Medical Systems, Inc. has been providing customers with innovative medical products and service excellence for 60 years. The company is a leader in production and supply of lung ventilation technology to nuclear medicine practitioners throughout the world.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to plans and projections. These statements may be identified by the fact that they use words such as "anticipate," "estimate," "believe" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Company Contacts:

Glenn Alto, President and CEO
Pharmalucence, Inc.
781-275-7120

James Reiss, President and CEO
Biodex Medical Systems, Inc.
631-924-9000